These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 18958546)

  • 41. Cyclophosphamide pulse therapy followed by azathioprine or methotrexate induces long-term remission in patients with steroid-refractory Crohn's disease.
    Schmidt C; Wittig BM; Moser C; Zeitz M; Stallmach A
    Aliment Pharmacol Ther; 2006 Jul; 24(2):343-50. PubMed ID: 16842461
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Crohn's disease outcome in patients under azathioprine: a tertiary referral center experience.
    Magro F; Santos-Antunes J; Vilas-Boas F; Rodrigues-Pinto E; Coelho R; Ribeiro OS; Lopes S; Macedo G
    J Crohns Colitis; 2014 Jul; 8(7):617-25. PubMed ID: 24332869
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-alpha, in the treatment of Crohn's disease: is its efficacy augmented by steroid-sparing immunosuppressive therapy? The Infliximab User Group.
    Mortimore M; Gibson PR; Selby WS; Radford-Smith GL; Florin TH;
    Intern Med J; 2001 Apr; 31(3):146-50. PubMed ID: 11478343
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tacrolimus versus intravenous pulse cyclophosphamide therapy in Chinese adults with steroid-resistant idiopathic minimal change nephropathy: a multicenter, open-label, nonrandomized cohort trial.
    Li H; Shi X; Shen H; Li X; Wang H; Li H; Xu G; Chen J
    Clin Ther; 2012 May; 34(5):1112-20. PubMed ID: 22503105
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease.
    Mantzaris GJ; Christidou A; Sfakianakis M; Roussos A; Koilakou S; Petraki K; Polyzou P
    Inflamm Bowel Dis; 2009 Mar; 15(3):375-82. PubMed ID: 19009634
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and efficacy of intravenous cyclophosphamide pulse therapy in therapy refractory Crohn's disease patients.
    Hirschmann S; Atreya R; Englbrecht M; Neurath MF
    J Physiol Pharmacol; 2017 Feb; 68(1):57-67. PubMed ID: 28456770
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Refractory enterovesical and duodenocolic fistulas in Crohn's disease successfully managed with tacrolimus.
    Fukuda A; Nakase H; Seno H; Nabeshima M; Sawada M; Chiba T
    J Gastroenterol; 2005 Apr; 40(4):433-5. PubMed ID: 15870981
    [No Abstract]   [Full Text] [Related]  

  • 48. The earliest trough concentration predicts the dose of tacrolimus required for remission induction therapy in ulcerative colitis patients.
    Hiraoka S; Kato J; Moritou Y; Takei D; Inokuchi T; Nakarai A; Takahashi S; Harada K; Okada H; Yamamoto K
    BMC Gastroenterol; 2015 Apr; 15():53. PubMed ID: 25925267
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Remission maintained by monotherapy after biological + immunosuppressive combination for Crohn's disease in clinical practice.
    Ampuero J; Rojas-Feria M; Castro-Fernández M; Millán-Lorenzo M; Guerrero-Jiménez P; Romero-Gómez M
    J Gastroenterol Hepatol; 2016 Jan; 31(1):112-8. PubMed ID: 26173493
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Successful use of infliximab and tacrolimus in a patient with Crohn's disease.
    Cortes X; Borrás-Blasco J; Rodríguez J; Moreno M; Molés JR; Castera E
    Int J Clin Pharmacol Ther; 2015 Aug; 53(8):692-6. PubMed ID: 25997551
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease.
    Yacyshyn BR; Barish C; Goff J; Dalke D; Gaspari M; Yu R; Tami J; Dorr FA; Sewell KL
    Aliment Pharmacol Ther; 2002 Oct; 16(10):1761-70. PubMed ID: 12269969
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adalimumab for maintenance of remission in Crohn's disease.
    Townsend CM; Nguyen TM; Cepek J; Abbass M; Parker CE; MacDonald JK; Khanna R; Jairath V; Feagan BG
    Cochrane Database Syst Rev; 2020 May; 5(5):CD012877. PubMed ID: 32413933
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Azathioprine discontinuation earlier than 6 months in Crohn's disease patients started on anti-TNF therapy is associated with loss of response and the need for anti-TNF dose escalation.
    Viazis N; Koukouratos T; Anastasiou J; Giakoumis M; Triantos C; Tsolias C; Theocharis G; Karamanolis DG
    Eur J Gastroenterol Hepatol; 2015 Apr; 27(4):436-41. PubMed ID: 25874518
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Response of refractory colitis to intravenous or oral tacrolimus (FK506).
    Fellermann K; Tanko Z; Herrlinger KR; Witthoeft T; Homann N; Bruening A; Ludwig D; Stange EF
    Inflamm Bowel Dis; 2002 Sep; 8(5):317-24. PubMed ID: 12479646
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Infliximab treatment of pediatric refractory Crohn's disease: a case report.
    Akman SA; Arikan C; Sözen G; Oztürk C; Yağci RV
    Turk J Gastroenterol; 2006 Jun; 17(2):133-6. PubMed ID: 16830299
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anti-tumor necrosis factor agents reduce corticosteroid use compared with azathioprine in patients with Crohn's disease.
    Kane SV; Jaganathan S; Bedenbaugh AV; Palmer L; Schwartz DA
    Curr Med Res Opin; 2014 Sep; 30(9):1821-6. PubMed ID: 24884302
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The efficacy of oral tacrolimus in patients with moderate/severe ulcerative colitis not receiving concomitant corticosteroid therapy.
    Inoue T; Murano M; Narabayashi K; Okada T; Nouda S; Ishida K; Kawakami K; Abe Y; Takeuchi T; Tokioka S; Umegaki E; Higuchi K
    Intern Med; 2013; 52(1):15-20. PubMed ID: 23291669
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Maintenance of remission in Crohn's disease.
    Gonvers JJ; Juillerat P; Mottet C; Felley C; Burnand B; Vader JP; Michetti P; Froehlich F
    Digestion; 2005; 71(1):41-8. PubMed ID: 15711049
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Maintenance therapy in Crohn's disease.
    Steinhart H
    Can J Gastroenterol; 2000 Sep; 14 Suppl C():23C-28C. PubMed ID: 11023557
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Cyclosporin A therapy in steroid-refractory patients with chronic inflammatory bowel diseases].
    Dejaco C; Gasché C; Reinisch W; Moser G; Novacek G; Tillinger W; Vogelsang H; Gangl A
    Wien Klin Wochenschr; 1998 Sep; 110(16):579-84. PubMed ID: 9782579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.